AB0152 The differential diagnostic specificities of purine enzymes activity in rheumatoid arthritis and gout

Abstract

Conclusion UGI hospitalisation rates were 2-4x lower, and less UGI-related healthcare resources were utilised for celecoxib-vs NSAID-treated patients. The incidence of serious clinical UGI safety endpoints was significantly lower in the celecoxib-treated patients. Sponsored by Pharmacia Corporation and Pfizer, Inc.